These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28588291)

  • 21. Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity.
    Feng Y; Sun X; Ye X; Feng Y; Wang J; Zheng X; Liu X; Yi C; Hao M; Wang Q; Li F; Xu W; Li L; Li C; Zhou R; Chen L; Feng L
    Virology; 2018 May; 518():272-283. PubMed ID: 29550678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.
    Thorner AR; Vogels R; Kaspers J; Weverling GJ; Holterman L; Lemckert AA; Dilraj A; McNally LM; Jeena PM; Jepsen S; Abbink P; Nanda A; Swanson PE; Bates AT; O'Brien KL; Havenga MJ; Goudsmit J; Barouch DH
    J Clin Microbiol; 2006 Oct; 44(10):3781-3. PubMed ID: 17021110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.
    Qiu H; Li X; Tian X; Zhou Z; Xing K; Li H; Tang N; Liu W; Bai P; Zhou R
    J Virol; 2012 Aug; 86(15):7964-75. PubMed ID: 22623776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.
    Mast TC; Kierstead L; Gupta SB; Nikas AA; Kallas EG; Novitsky V; Mbewe B; Pitisuttithum P; Schechter M; Vardas E; Wolfe ND; Aste-Amezaga M; Casimiro DR; Coplan P; Straus WL; Shiver JW
    Vaccine; 2010 Jan; 28(4):950-7. PubMed ID: 19925902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
    Bradley RR; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
    J Virol; 2012 Jan; 86(1):625-9. PubMed ID: 22072776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in China.
    Huang D; Hennequi M; Elvachev A; Menguy T; Silvestre N; Yu D; Han Y; Inchauspé G; Zhang X; Zhu R
    Arch Virol; 2015 Apr; 160(4):1125-30. PubMed ID: 25616844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of Human Adenovirus Type 5 Neutralizing Antibody in Common Marmosets Determined by a New Set of Two Assays.
    Wang Q; Sun Y; Xu Y; Wang Y; Wang H; Fu Y; Allain JP; Li C; Li T
    Viral Immunol; 2019 Oct; 32(8):348-354. PubMed ID: 31433272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
    Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
    J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human parechovirus seroprevalence in Finland and the Netherlands.
    Westerhuis B; Kolehmainen P; Benschop K; Nurminen N; Koen G; Koskiniemi M; Simell O; Knip M; Hyöty H; Wolthers K; Tauriainen S
    J Clin Virol; 2013 Sep; 58(1):211-5. PubMed ID: 23891146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera.
    Luo Y; Xiong D; Li HH; Qiu SP; Lin CL; Chen Q; Huang CH; Yuan Q; Zhang J; Xia NS
    Virol J; 2016 Mar; 13():44. PubMed ID: 26987753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55.
    Liu T; Zhou Z; Tian X; Liu W; Xu D; Fan Y; Liao J; Gu S; Li X; Zhou R
    Vaccine; 2018 Apr; 36(16):2199-2206. PubMed ID: 29548605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.
    Nwanegbo E; Vardas E; Gao W; Whittle H; Sun H; Rowe D; Robbins PD; Gambotto A
    Clin Diagn Lab Immunol; 2004 Mar; 11(2):351-7. PubMed ID: 15013987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey.
    Ludwig SL; Brundage JF; Kelley PW; Nang R; Towle C; Schnurr DP; Crawford-Miksza L; Gaydos JC
    J Infect Dis; 1998 Dec; 178(6):1776-8. PubMed ID: 9815232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species: potential application for adenovirus seroepidemiology.
    Yu B; Dong J; Wang C; Wang Z; Gao L; Zhang H; Wu J; Kong W; Yu X
    J Gen Virol; 2014 Jul; 95(Pt 7):1564-1573. PubMed ID: 24764358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?
    Fausther-Bovendo H; Kobinger GP
    Hum Vaccin Immunother; 2014; 10(10):2875-84. PubMed ID: 25483662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007.
    Tate JE; Bunning ML; Lott L; Lu X; Su J; Metzgar D; Brosch L; Panozzo CA; Marconi VC; Faix DJ; Prill M; Johnson B; Erdman DD; Fonseca V; Anderson LJ; Widdowson MA
    J Infect Dis; 2009 May; 199(10):1419-26. PubMed ID: 19351260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A seroepidemiological survey of adenovirus type 7 circulation among healthy adults in China and in Sierra Leone, West Africa.
    Wang B; Li J; Wu S; Wang Y; Chen Y; Zhai Y; Song X; Zhao Z; Zhang Z; Zhang J; Yu R; Hou L; Chen W
    Front Public Health; 2023; 11():1095343. PubMed ID: 36815162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors.
    Piedra PA; Poveda GA; Ramsey B; McCoy K; Hiatt PW
    Pediatrics; 1998 Jun; 101(6):1013-9. PubMed ID: 9606228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.